Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
Conditions
Hidradenitis Suppurativa
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Saguaro Dermatology, Phoenix, Arizona, United States
First Oc Dermatology, Fountain Valley, California, United States
Amicis Research Center Valencia, Northridge, California, United States
Children'S Hospital of Orange County, Orange, California, United States
Clinical Trials Research Institute, Thousand Oaks, California, United States
Clarity Dermatology, Castle Rock, Colorado, United States
Advanced Pharma Cr, Llc, Miami, Florida, United States
International Clinical Research Tennessee Llc, Sanford, Florida, United States
Lenus Research Medical Group, Llc, Sweetwater, Florida, United States
Trueblue Clinical Research, Tampa, Florida, United States
Emory University School of Medicine, Atlanta, Georgia, United States
Lane Dermatology and Dermatologic Surgery, Columbus, Georgia, United States
Options Research Group, Llc, West Lafayette, Indiana, United States
Equity Medical, Llc, Bowling Green, Kentucky, United States
Delricht Research, Baton Rouge, Louisiana, United States
Revival Research Institute, Llc Troy, Troy, Michigan, United States
Red River Research Partners, Bolivar, Missouri, United States
Dr Bobby Buka, Md Greenwich Village, New York, New York, United States
Equity Medical, Llc, New York, New York, United States
Red River Research Partners, Fargo, North Dakota, United States
Centricity Research Columbus, Columbus, Ohio, United States
Unity Clinical Research, Oklahoma City, Oklahoma, United States
Paddington Testing Co Inc, Philadelphia, Pennsylvania, United States
Study leads
Incyte Medical Monitor
Study Director
Incyte Corporation